Expression Of Syndecan-1 And Its Clinical Significance In Breast Invasive Ductal Carcinoma

Objective:To investigate the expression of Syndecan-1 in epithelial cells of different breast tissues(normal breast tissue,breast fibroadenomas,breast ductal carcinoma in situ,breast invasive ductal carcinoma),and to analyze the correlation between the expression of Syndecan-1 in breast invasive ductal carcinoma epithelial cell and the clinicopathological features such as age,menstrual status,tumor diameter,lymph node metastasis and molecular typing,in order to exploring the clinical significance of Syndecan-1 in breast invasive ductal carcinoma,providing clinical data support for its clinical application.Methods: 1.The postoperative pathological specimens were diagnosed as 106 cases of breast invasive ductal carcinoma,62 cases of breast ductal carcinoma in situ,60 cases of breast fibroadenoma,and 65 cases of normal breast tissue are divided into 4 groups.2.Immunohistochemistry was used to detect the expression of Syndecan-1 in the above specimens.3.Comparing the expression of Syndecan-1 in the epithelial cells of 4 groups of breast tissue.4.Collecting clinicopathological data(including age,menstrual status,primary tumor diameter,axillary lymph node status,distant metastasis,histological grade,molecular typing,and immunohistochemical correlation markers)in breast invasive ductal carcinomapatients.5.Analysising the correlation between the expression of Syndecan-1 in epithelial cells of breast invasive ductal carcinoma with its clinicopathological data,molecular typing and immunohistochemical markers.Results: 1.Syndecan-1 was strongly expressed in normal breast tissue and breast fibroadenoma tissue epithelial cells(91.8%,86.7%,),the expression was weakened and the expression rate was decreased in breast ductal carcinoma in situ and breast invasive ductal carcinoma(56.5%,48.1%),and the expression of Syndecan-1 was significantly different in 4 breast tissues(P<0.001);There was no difference between normal tissue and breast fibroadenoma(P=0.467);there was no difference in breast ductal carcinoma in situ and breast invasive ductal carcinoma(P=0.297);whereas there was a difference in expression of Syndecan-1 in normal/benign tissue of the breast and breast ductal carcinoma in situ/breast invasive ductal carcinoma(P<0.001).2.In breast invasive ductal carcinoma,the high expression of Syndecan-1 is not related to the patient’s age,menstrual status,primary tumor diameter,but is related to axillary lymph node status,histological grade and tumor stage.The high expression rate of Syndecan-1 in axillary lymph node positive patients was lower than that in axillary lymph node negative(35.5% vs.65.9%,P=0.002);the high expression rate in histological grade 3 was lower than that in histology 1 and 2(25.0% vs.52.2%,P=0.045;the high expression rate in stage III and IV was lower thanthat of stage I and II(27.75% vs.64.4%,P<0.001).3.The high expression of Syndecan-1 in breast invasive ductal carcinoma is related to ER expression,and has nothing to do with the expression of PR,Her-2 and Ki-67.The expression rate of Syndecan-1 was significantly higher in ER-positive breast cancer than in ER-negative breast cancer(55.9% vs.34.2%,P=0.032);Kendall,s tau_b analysis showed the correlation between the expression of Syndecan-1 and ER in breast cancer(r=0.208,P=0.032),that suggested the high expression of Syndecan-1 in breast cancer was positively correlated with ER positive expression.4.The expression of Syndecan-1 was different in four subtypes breast invasive ductal carcinoma(P=0.044),and the high expression rate of Syndecan-1 in Luminal A breast cancer was higher than that in Her-2 overexpressing breast cancer,and the difference was statistically significant(67.7% vs.26.7%,P=0.009);there was no difference between the other subtypes,and there was no difference between Luminal and non-Luminal breast cancer(53.40% Vs.36.4%,P=0.245),there was no difference between the triple-negative and non-triple-negative breast cancer(44.4% vs.49.4%,P=0.399).5.Screening of clinicopathological parameters(axillary lymph node status,histological grade,tumor stage,ER expression and molecular typing)associated with the expression of Syndecan-1 in breast invasive ductal carcinoma as covariates,and multivariate logistic regression analysis showed tumor stage and molecular typing are independent correlative factors for the expression of Syndecan-1 in breast invasive ductal carcinoma.Conclusion: 1.In the normal tissues of breast,breast fibroadenomas,breast ductal carcinoma in situ,breast invasive ductal carcinoma,the high expression rate of Syndecan-1 is gradually reducing.Down-regulation of expression of Syndecan-1 in breast ductal carcinoma in situ and breast invasive ductal carcinoma may be associated with the development of breast cancer.2.In breast invasive ductal carcinoma,the low expression rate of Syndecan-1 is associated with high lymph node metastasis status,high histological grade,high tumor stage,poor molecular typing and ER-negative expression.Multivariate analysis of tumor staging and molecular typing is Independently related factors in the expression of Syndecan-1 in invasive ductal carcinoma of the breast indicate that the low expression of Syndecan-1 is associated with a malignant invasive phenotype of breast invasive ductal carcinoma.